Chronic News and Research

RSS

CardioFocus completes $30.6M private financing

CardioFocus, Inc., developer of the Endoscopic Ablation System for the transcatheter treatment of Atrial Fibrillation, announced the completion of a $30.6M private financing.

28 Feb 2011

Global Genes Project, 46NYC introduce t-shirts to create awareness about lack of drug treatments for rare disease

Wear That You Care. Today is Rare Disease Day and 46NYC is helping raise awareness for an important cause – this time the drug development crisis facing the rare disease patient community worldwide.

28 Feb 2011

Researchers to examine thrombolysis for treatment of DVT in leg

Blood clots in the leg occur commonly. In one-half of the cases, the blood clot will break loose and travel through the bloodstream to the lungs - which may be life-threatening.

28 Feb 2011

Scientists identify new pathogen linked to childhood dental disease

Researchers at The Forsyth Institute have made a significant discovery about the nature of childhood dental disease. The scientific studies led by Anne Tanner, BDS, Ph.D., identified a new pathogen connected to severe early childhood caries.

28 Feb 2011

Study: Fish oil may prevent muscle and weight loss in cancer patients during chemotherapy

A new analysis has found that supplementing the diet with fish oil may prevent muscle and weight loss that commonly occurs in cancer patients who undergo chemotherapy. Published early online in Cancer, a peer-reviewed journal of the American Cancer Society, the study indicates that fish oil may help combat cancer-related malnutrition.

28 Feb 2011

AHRQ: $52.2 billion spent on prescription drugs for treatment of metabolic conditions during 2008

Insurers and consumers spent $52.2 billion on prescription drugs in 2008 for outpatient treatment of metabolic conditions such as diabetes and elevated cholesterol, according to the latest News and Numbers from the Agency for Healthcare Research and Quality.

28 Feb 2011

FDA approves GSK's PROMACTA to treat rare blood disorder

GlaxoSmithKline today announced that the United States Food and Drug Administration granted full approval for PROMACTA, an oral tablet that can raise platelet counts in patients with the rare blood disorder chronic immune thrombocytopenic purpura who have had an insufficient response to corticosteroids, immunoglobulins or splenectomy.

27 Feb 2011

Study: HT may affect symptom load and quality of life unrelated to hypothyroidism

Hashimoto's thyroiditis, an inflammatory disorder of the thyroid, is the most common cause of hypothyroidism, but a study has suggested that even when thyroid function is normal, HT may increase symptoms and decrease quality of life, as described in an article in Thyroid, a peer-reviewed journal published by Mary Ann Liebert, Inc.

27 Feb 2011

Lyme’s disease and chronic fatigue syndrome biomarkers found

A new study shows that spinal fluid can be used to detect proteins that help distinguish patients with Lyme disease from those with chronic fatigue syndrome.

27 Feb 2011

Less-toxic combination of immune-based drug and chemotherapy drug produce long-term remissions in CLL

New research shows that a less-toxic combination of a targeted immune-based drug and a chemotherapy drug can produce long-term remissions in some chronic lymphocytic leukemia patients. And it does so without increasing the risk of later therapy-related myelodysplastic syndrome and acute myeloid leukemia, which can often occur with a three-drug combination used to treat these patients.

25 Feb 2011

Research Roundup: Health costs at life's end; Assessing hospital quality; Surgeons' burnout; Per capita Medicaid spending

Annals of Internal Medicine: Determinants Of Medical Expenditures In The Last 6 Months Of Life - Identifying factors about patients in the final six months of life that affect the level of care needed "may reveal opportunities for patient-centered interventions to predict and to reduce medical costs," write the authors, while noting that the study had "a large proportion of unexplained variation."

25 Feb 2011

CIGNA's integrated disability and medical programs reduce workplace absence

Employees who have both disability and medical coverage from CIGNA, and who also suffer a short-term disabling illness or injury, return to work more often and spend less time away from work on leave than those without the integrated program. This is the conclusion of a new study by CIGNA comparing integrated and non-integrated disability and medical plans.

25 Feb 2011

Preclinical data of Zalicus sodium channel compound published in journal PAIN

Zalicus Inc. today announced the publication of preclinical data in the journal PAIN. The paper describes the activity of Z212, a novel proprietary small organic compound that acts to modulate Nav1.7 and Nav1.8 sodium channels and to reduce neuropathic pain by targeting the hyper-excitability associated with chronic pain signaling pathways.

25 Feb 2011

Medwell commits $2,000,000 investment in Mimetogen

Medwell Capital Corp. today announced that it has committed to invest up to $2,000,000 in Mimetogen Pharmaceuticals Inc. ("Mimetogen"), a privately-held, clinical-stage company developing a treatment for dry eye disease. Medwell Capital participated in a Series B equity financing with existing Mimetogen investors, iNovia Capital, MSBi Valorisation and VIMAC Milestone Medica.

25 Feb 2011

New policy research brief examines patients at risk of losing care under health center spending cuts

A new policy research brief released today by the Geiger Gibson/RCHN Community Health Foundation Research Collaborative at The George Washington University School of Public Health and Health Services examines the characteristics of patients whose access to health center services is at risk because of a potential $1.3 billion in direct spending cuts for community health centers.

25 Feb 2011

AMAG fourth quarter total revenues increase to $17.2 million

AMAG Pharmaceuticals, Inc. a biopharmaceutical company focused on the development and commercialization of a therapeutic iron compound to treat iron deficiency anemia, today reported unaudited consolidated financial results for the fourth quarter and year ended December 31, 2010.

25 Feb 2011

Savient launches KRYSTEXXA in the U.S.

Savient Pharmaceuticals, Inc. announced the official full U.S. commercial launch of KRYSTEXXA™ (pegloticase), which has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of chronic gout in adult patients refractory to conventional therapy. KRYSTEXXA is now the first and only therapy available to address this unmet medical need.

25 Feb 2011

Research sheds new light on problem of insulin resistance in type 2 diabetes

A research team, led by La Jolla Institute scientist Joel Linden, Ph.D., has shed new light on the problem of insulin resistance, and identified the key participants in a molecular pathway that holds therapeutic promise for reducing the severity of type 2 diabetes.

25 Feb 2011

Harvard Medical School selects Agilent's NMR spectrometer for biomolecular research applications

Agilent Technologies Inc. today announced that Harvard Medical School has selected Agilent's 700-MHz Ultra-High Field Nuclear Magnetic Resonance spectrometer for biomolecular research applications.

25 Feb 2011

PHA partners with NORD, EURORDIS to raise global awareness about PH

Pulmonary hypertension is a rare, under-diagnosed disease that can strike people at any time, affecting newborns to the elderly or anyone in between. To raise global awareness of this invisible disease, the Pulmonary Hypertension Association is partnering with the National Organization for Rare Disorders and Rare Diseases Europe on Feb. 28, 2011, to observe Rare Disease Day.

25 Feb 2011

Chronic News and Research

CardioFocus completes $30.6M private financing

Global Genes Project, 46NYC introduce t-shirts to create awareness about lack of drug treatments for rare disease

Researchers to examine thrombolysis for treatment of DVT in leg

Scientists identify new pathogen linked to childhood dental disease

Study: Fish oil may prevent muscle and weight loss in cancer patients during chemotherapy

AHRQ: $52.2 billion spent on prescription drugs for treatment of metabolic conditions during 2008

FDA approves GSK's PROMACTA to treat rare blood disorder

Study: HT may affect symptom load and quality of life unrelated to hypothyroidism

Lyme’s disease and chronic fatigue syndrome biomarkers found

Less-toxic combination of immune-based drug and chemotherapy drug produce long-term remissions in CLL

Research Roundup: Health costs at life's end; Assessing hospital quality; Surgeons' burnout; Per capita Medicaid spending

CIGNA's integrated disability and medical programs reduce workplace absence

Preclinical data of Zalicus sodium channel compound published in journal PAIN

Medwell commits $2,000,000 investment in Mimetogen

New policy research brief examines patients at risk of losing care under health center spending cuts

AMAG fourth quarter total revenues increase to $17.2 million

Savient launches KRYSTEXXA in the U.S.

Research sheds new light on problem of insulin resistance in type 2 diabetes

Harvard Medical School selects Agilent's NMR spectrometer for biomolecular research applications

PHA partners with NORD, EURORDIS to raise global awareness about PH

Industry Focus eBook - Cell biology (5th edition) eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News